Innovative Medicines Canada / Médicaments novateurs Canada
Registration:
1
of
1
(2023-09-28
to
2024-01-01)
Legislative Proposal, Bill or Resolution
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
- Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
- Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products
- Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19
Policies or Program
- Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
- The government's Science and Technology strategy as it relates to the biopharmaceutical industry
Regulation
- Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
- Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry